Cardiology

doi: 10.25005/2074-0581-2022-24-3-317-323
PREVALENCE OF CORONARY ARTERY DISEASE IN YOUNG AND MIDDLE AGE PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION

Kh.Yo. Sharipova1, D.D. Rakhimov1, R.G. Sokhibov2, R.M. Gulova1, D.U. Kosimova3

1Department of Propaedeutics of Internal Diseases, Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan
2Department of Internal Diseases № 2 Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan
3National Medical Center «Shifobakhsh» of the Republic of Tajikistan, Dushanbe, Republic of Tajikistan

Objective: To establish the frequency of different forms of coronary artery disease (CAD) in patients with resistant arterial hypertension (AH).

Methods: Based on the data from clinical and anamnestic studies and the results of electrocardiography (ECG), Holter ECG monitoring (HM-ECG), and bicycle ergometry (VEM), 370 young and middle-aged patients (WHO, 1965), the mean age 54.1±4, with primary AH were diagnosed with CAD according to the Canadian classification (World Health Organization (WHO), 1979; with additions by All-Union Cardiology Research Centre, 1995). With daily monitoring of blood pressure (BP) against the background of antihypertensive therapy (AHT), groups of patients with controlled (CAH; n=84) and resistant (RAH; n=286) arterial hypertension were identified.

Results: It was found that in young and middle-aged patients with both CAH and RAH, the frequency of stable angina pectoris (SA) was the highest, mainly due to functional classes (FC) I-II; severe functional classes of SA, and unstable angina (UA) were markedly less frequent; less than a quarter of patients had a myocardial infarction (MI), mainly due to non-Q-wave MI (non-Q-MI). In patients with CAH and RAH FC I-II of SA were predominant (in 70.2% of patients with CAH and 34.3% with RAH; p=0.0001), while FC III-IV of SA were mainly observed against the background of RAH (21% vs. 5% in patients with CAH, p=0.0015). In patients of young and middle age, against the background of RAH, the frequency of UA (18.9%; p=0.0220) and the total number of MI (25.9%; p=0.0482) was higher, than in CAH, mainly due to Q-MI (11.2%; p=0.0360), indicating the severity of coronary insufficiency. The increase in non-Q-MI against the background of RAH was statistically insignificant (p=0.5191).

Conclusion: The ratio of the frequency of different forms of CAD against the background of CAH and RAH was unidirectional. However, the overall frequency of severe forms of CAD (UA and MI, especially Q-MI) in patients with RAH significantly exceeded those in patients with CAH, which allowed us to consider RAH as a factor in the progressive course of CAD.

Keywords: Coronary artery disease, stable angina, unstable angina, myocardial infarction, resistant arterial hypertension, young and middle age.

Download file:


References
  1. Konradi AO. Konservativnaya lekarstvennaya terapiya patsientov s rezistentnoy arterial’noy gipertenziey – vremya kompromissa [Conservative drug therapy for resistant hypertension patients – a time for compromise]. Meditsinskiy sovet. 2013;9(1):17-25.
  2. Chazova IE, Zhernakova YuV. Diagnostika i lechenie arterial’noy gipertonii [Diagnosis and treatment of arterial hypertension]. Sistemnye gipertenzii. 2019;16(1):6-31.
  3. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-69.
  4. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2015 update. Circulation. 2015;131(4):434-41.
  5. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: Systematic review and meta-analysis of prospective studies. J Hypertens. 2012;30(3):449-56.
  6. Tucker KL, Sheppard JP, Stevens R, Bosworth HB, Bove А, Bray EP, et al. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLoS Med. 2017;14(9):e1002389. Available from: https://doi.org/10.1371/journal.pmed.1002389
  7. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/ PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71(6):1269-324. Available from: https:// doi.org/10.1161/ HYP.0000000000000066
  8. Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71. Available from: https:// doi.org/10.1016/S0140-6736(14)61682-2
  9. Salles GF, Reboldi G, Fagard RH, Cardoso CR, Pierdomenico SD, Verdecchia P, et al. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: The Ambulatory Blood pressure Collaboration in patients with Hypertension (ABC-H) meta-analysis. Hypertension. 2016;67(4):693-700. Available from: https://doi.org/10.1161/HYPERTENSIONAHA. 115.06981
  10. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: Overview and meta-analyses of randomized trials. J Hypertens. 2017;35(11):2150-60. Available from: https://doi.org/10.1097/ HJH.0000000000001547
  11. Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: Results from ONTARGET and TRANSCEND trials. Lancet. 2017;389(10085):2226-37.
  12. Nozirov DKh, Narzulloyeva AR, Shokirov TM. Rasprostranyonnost' arterial'noy gipertenzii i ishemicheskoy bolezni serdtsa sredi neorganizovannoy populyatsii Ganchinskogo rayona Sogdiyskoy oblasti [Prevalence of arterial hypertension and coronary heart disease among unorganized population of Ganchi district of Sughd]. Vestnik poslediplomnogo obrazovaniya v sfere zdravookhraneniya. 2015;3:40-5.
  13. Rudoy AS. Khronicheskie koronarnye sindromy: obzor rekomendatsiy ESC-2019 [Chronic coronary syndromes: A review of the recommendations of the ESC- 2019]. Neotlozhnaya kardiologiya i kardioovaskulyarnye riski. 2019;3(2):636- 52.
  14. Williams B, Mancia G, Spiering W, Agabiti RE, Azizi М, Burnier М, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953- 2041. Available from: https://doi.org/10.5603/KP.2019.0018
  15. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53-90. Available from: https://doi.org/10.1161/ HYP.0000000000000084
  16. Chazova IE, Fomin VV, Razuvaeva MA, Vigdorchik AV. Epidemiologicheskaya kharakteristika rezistentnoy i nekontroliruemoy arterial’noy gipertenzii v Rossiyskoy Federatsii (Rossiyskiy registr nekontroliruemoy i rezistentnoy arterial’noy gipertenzii REGATA-PRIMA «Rezistentnaya gipertoniya arterial’naya – prichiny i mekhanizmy razvitiya») [Epidemiological characteristics of resistant and uncontrolled arterial hypertension in the Russian Federation (Russian register of uncontrolled and resistant arterial hypertension REGATA-PRIMA "Resistant arterial hypertension – causes and mechanisms of development")]. Sistemnye gipertenzii. 2010;7(3).34-41
  17. Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: A meta-analysis of randomised controlled trials. Heart Lung Circ. 2016;25(10):1021-30. Available from: https://doi.org/10.1016/j. hlc.2016.02.016
  18. Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2017;39(6):520-6. Available from: https://doi.org/10.1080/10641963.2017.1 281947
  19. Aksyonova AV, Esaulova TE, Sivakova OA, Chazova IE. Rezistentnaya i refrakternaya arterial’nye gipertenzii: skhodstva i razlichiya, novye podkhody k diagnostike i lecheniyu [Resistant and refractory arterial hypertension: Similarities and differences, new approaches to diagnosis and treatment]. Sistemnye gipertenzii. 2018;15(3):11-3. Available from: https://doi.org/10.26442/2075- 082X_2018.3.11-13
  20. Kasiakogias A, Tsioufis C, Dimitriadis K, Konstantinidis D, Koumelli A, Leontsinis I. Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives: A 4-year follow-up study. Journal of Human Hypertension. 2018;32(7):487-93. Available from: doi.org/10.1038/s41371-018- 0065-y
  21. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. Hypertension. 2014;32(3):e635-43. Available from: https://doi.org/10.1097/HJH.0000000000000051

Authors informations:

Sharipova Khursand Yodgorovna
Doctor of Medical Sciences, Full Professor, Professor of the Department of Propaedeutics of Internal Diseases, Avicenna Tajik State Medical University
ORCID ID: 0000-0001-9340-5215
SPIN: 5685-9944
Author ID: 846918
E-mail: sharipovakh@mail.ru

Rakhimov Dzhasur Dzhumaboevich
Postgraduate Student of the Department of Propaedeutics of Internal Diseases, Avicenna Tajik State Medical University
ORCID ID: 0000-0003-3376-1722
E-mail: jasur5000@yandex.ru

Sokhibov Rakhmatullo Gulomovich
Candidate of Medical Sciences, Head of the Department of Internal Diseases № 2, Avicenna Tajik State Medical University
ORCID ID: 0000-0002-2413-9299
E-mail: rahmatulosokhibovgmail.com

Gulova Rukhshona Makhmadshoevna
Postgraduate Student of the Department of Propaedeutics of Internal Diseases, Avicenna Tajik State Medical University
ORCID ID: 0000-0002-4695-223X
E-mail: komron909@mail.ru

Kosimova Dilafruz Umarovna
Resident of the 2nd Department of Neurology, «Shifobakhsh» National Medical Center of the Republic of Tajikistan
ORCID: 0000-0002-1472-0549
E-mail: kasymova.dilafruz@mail.ru

Information about the source of support in the form of grants, equipment, and drugs

The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflict of interest: No conflict

Address for correspondence:

Sharipova Khursand Yodgorovna
Doctor of Medical Sciences, Full Professor, Professor of the Department of Propaedeutics of Internal Diseases, Avicenna Tajik State Medical University

734003, Republic of Tajikistan, Dushanbe, Rudaki Ave., 139

Tel.: +992 (935) 811297

E-mail: sharipovakh@mail.ru

Materials on the topic: